Back to News

Celerion Transforms the Consent Experience for Sites and Patients with ³Ô¹Ï±¬ÁÏ eConsent

³Ô¹Ï±¬ÁÏ eConsent simplifies patient informed consent for greater efficiency and compliance

BARCELONA, Spain ¡ª 6 Oct. 2021 ¡ª ³Ô¹Ï±¬ÁÏ Systems (NYSE: VEEV) today announced that Celerion adopted ³Ô¹Ï±¬ÁÏ eConsent, a My³Ô¹Ï±¬ÁÏ for Patients solution, to complete electronic consent for its Phase I clinical trials. With ³Ô¹Ï±¬ÁÏ eConsent, Celerion is shifting from manual and paper-based informed consent to a completely digital process. The company is using ³Ô¹Ï±¬ÁÏ eConsent across multiple studies and has consented more than 200 subjects.

¡°COVID-19 limited our time with participants, so we needed new and digital ways to keep our studies moving forward while remaining fully compliant with regulatory requirements regarding obtaining proper consent,¡± said Staci McDonald, executive director, scientific clinical operations at Celerion. ¡°³Ô¹Ï±¬ÁÏ eConsent gives us an easy-to-use solution that can keep up with our fast-paced environment and improve participant comprehension of study procedures. Deploying the solution went smooth, with positive feedback from study teams, on-site staff, and participants.¡±

A global leader in early clinical research services, Celerion uses ³Ô¹Ï±¬ÁÏ SiteVault to digitally author, manage, and distribute informed consent forms (ICF). Patients can then access the eConsent document securely and complete the consenting process via a mobile device. This simplifies document reconciliation and reduces the administrative burden on sites. With a seamless flow of information, Celerion has complete visibility into consent status for improved study compliance and oversight.

¡°Celerion is advancing how the industry works together by using digital solutions that enable patient-centric, paperless clinical trials,¡± said Tim Davis, vice president, My³Ô¹Ï±¬ÁÏ for Patients at ³Ô¹Ï±¬ÁÏ Systems. ¡°³Ô¹Ï±¬ÁÏ eConsent improves the informed consent process for all parties involved by delivering an intuitive and digital experience for patients and easy collaboration with sites and IRBs for sponsors.¡±

Learn how Celerion modernized the patient consenting process at the upcoming ³Ô¹Ï±¬ÁÏ R&D and Quality Summit Connect, 14 October 2021. The online event is open to life sciences industry professionals. Register and stay up to date on program details at veeva.com/Summit.

Additional Information
For more on ³Ô¹Ï±¬ÁÏ eConsent, visit: veeva.com/eu/eConsent
Connect with ³Ô¹Ï±¬ÁÏ on LinkedIn:
Follow @veeva_eu on Twitter:

About ³Ô¹Ï±¬ÁÏ Systems
³Ô¹Ï±¬ÁÏ is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, ³Ô¹Ï±¬ÁÏ serves more than 1,000 customers, ranging from the world¡¯s largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, ³Ô¹Ï±¬ÁÏ is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.

Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of ³Ô¹Ï±¬ÁÏ¡¯s products and services, the results from use of ³Ô¹Ï±¬ÁÏ¡¯s products and services, and general business conditions, particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon ³Ô¹Ï±¬ÁÏ¡¯s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent ³Ô¹Ï±¬ÁÏ¡¯s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and ³Ô¹Ï±¬ÁÏ disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect ³Ô¹Ï±¬ÁÏ¡¯s financial results are included under the captions, ¡°Risk Factors¡± and ¡°Management¡¯s Discussion and Analysis of Financial Condition and Results of Operations,¡± in the company¡¯s filing on Form 10-Q for the period ended July 31, 2021. This is available on the company¡¯s website at veeva.com under the Investors section and on the SEC¡¯s website at . Further information on potential risks that could affect actual results will be included in other filings ³Ô¹Ï±¬ÁÏ makes with the SEC from time to time.

###

Contact:

Deivis Mercado
³Ô¹Ï±¬ÁÏ Systems
925-226-8821
deivis.mercado@veeva.com

Jeremy Whittaker
³Ô¹Ï±¬ÁÏ Systems
+49 6950955486
jeremy.whittaker@veeva.com

Powerful Community, Fresh Ideas

Copenhagen | 28-29 May, 2026

Learn more